Pfizer: Caremate

A digital solution helping advanced stage renal cancer patients manage their treatment has already been adopted by New Zealand patients and is catching on quickly across the Tasman. Patients are often burdened with the added stress of complex treatment schedules that are difficult to follow. While the advantage of oral treatment is that it is less invasive on patient's lives, the flip side of this can be less contact with healthcare professionals, and fewer opportunities to discuss symptoms. Pfizer manufactures a leading medication for renal cancer patients. The Caremate programme was prompted by research gathered by Pfizer NZ in an effort to understand how to improve the lives of renal cancer patients and go beyond medication with comprehensive care. Agency:DDB, New Zealand